MOSCOW (Reuters) - Russia’s sovereign wealth fund said on Friday it had agreed to supply up to 35 million doses of the Russian experimental vaccine against COVID-19 to Uzbekistan’s Laxisam, a pharmaceutical company.
The deal is one of several agreed by the Russian Direct Investment Fund (RDIF) in recent weeks to supply the vaccine, which is currently being tested in a large-scale trial in Moscow, abroad.
It has also inked supply deals with Kazakhstan, India, Mexico and two states in Brazil.
Reporting by Anastasia Teterevleva; writing by Polina Ivanova; Editing by Alex Richardson
Our Standards: The Thomson Reuters Trust Principles.